ERBB2 and cancer: It would be clinically inefficient to evaluate the HER2 status of both the primary cancer and metastatic ALN using IHC/FISH analysis, which requires the time-consuming process of slide preparation, and is mainly applicable to tissue samples obtained by surgical or core needle biopsy [32].